Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Core Insights - Lyell Immunopharma, Inc. announced the acceptance of three abstracts for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from Nov. 6-10, 2024, in Houston, TX, focusing on its pipeline of cell therapies and anti-exhaustion technology [1][2][4] Group 1: Clinical Trials and Presentations - The first presentation will showcase translational data from the LYL797 Phase 1 clinical trial, highlighting solid tumor infiltration and cell killing by reprogrammed ROR1 CAR T cells [2] - The second presentation will discuss multiomic profiling of LYL119, a reprogrammed ROR1 CAR T product, which generates T cells with reduced exhaustion and enhanced memory characteristics [3] - The third presentation will focus on utilizing Stim-R™ Technology to reduce irradiated feeder cells in the tumor-infiltrating lymphocyte culture process [3] Group 2: Company Overview - Lyell is a clinical-stage T-cell reprogramming company with a diverse pipeline of cell therapies, including three product candidates in or entering Phase 1 clinical development for solid tumors and hematologic malignancies [4] - The company employs novel anti-exhaustion technology to address barriers such as T-cell exhaustion and lack of durable stemness, aiming for improved clinical outcomes [4] - Lyell is based in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington [4]